TCTR20210920005招募中2 期
Immunogenicity and safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescent (age 12-17 years) in Thailand.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 Years 至 30 Years（—）
- 性别
- All
入选标准
- •1. age 12-30 year old
- •2. no active underlying disease.
- •3. informed to participated the study.
排除标准
- •1. previous infection with SAR-CoV-2
- •2. previous received SAR-CoV-2 vaccine
- •3. receive any vaccine with 14 days
- •4. Fever at vaccination day
- •5. History of URI within 14 days
- •6. History of seizure.
- •7. Abnormal development
- •8. Pregnancy.
- •9. Lactation.
- •10. History of severe allergy to vaccine.
研究者
相似试验
尚未招募
3 期
Immunogenicity and safety after vaccinated with BBIBP-CorV (COVID-19 vaccine) in Thai pregnant womePregnant womenCOVID-19SARS-CoV-2 vaccineVaccinePregnantBBIBP-CorVSinopharmTCTR20210923013Chulabhorn Hospital400
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005367-27-SKBIOVOMED
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005366-35-CZBIOVOMED
尚未招募
4 期
â??Comparative evaluation of immunogenicity of bivalent oral poliovirus vaccine (bOPV) and monovalent oral poliovirus vaccine type 1 (mOPV1) with a dose of inactivated polio vaccine (IPV) at week 14CTRI/2016/04/006826Panacea Biotec Ltd600
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisRheumatoid arthritisEUCTR2012-002945-40-ESBoehringer Ingelheim International GmbH600